The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Anja Hviid Simonsen, Bea Kuiperij, Omar Ali El-Agnaf, Sebastian Engelborghs, Sanna Kaisa Herukka, Lucilla Parnetti, Irena Rektorova, Eugeen Vanmechelen, Elisabeth Kapaki, Marcel Verbeek, Brit Mollenhauer

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

Original languageEnglish
Pages (from-to)19-34
Number of pages16
JournalBiomarkers in Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

    Fingerprint

Keywords

  • biomarker
  • CSF
  • diagnosis
  • ELISA
  • Parkinson's disease
  • α-synuclein

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery
  • Medicine(all)

Cite this

Simonsen, A. H., Kuiperij, B., Ali El-Agnaf, O., Engelborghs, S., Herukka, S. K., Parnetti, L., Rektorova, I., Vanmechelen, E., Kapaki, E., Verbeek, M., & Mollenhauer, B. (2016). The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomarkers in Medicine, 10(1), 19-34. https://doi.org/10.2217/BMM.14.105